Latest From Norgine BV
A European firm with significant operations in the UK, Norgine has invested considerable resources in preparing for Brexit. With less than three weeks to go before the UK is scheduled to leave the EU, chief operating officer Peter Martin is very concerned about the risks of a no-deal Brexit, and the lack of clarity on what will happen next.
Germany’s OTC Market in 2018: Online Sees Double-Digit Growth, Bionorica’s Canephron Uno Tops New Launches
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.
- Diagnostic Imaging Equipment & Supplies
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Neurology, Nervous System
- Norgine International Ltd.
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Norgine BV
- Senior Management
Peter Stein, Chmn. & CEO
Christopher Bath, CFO
Paul Pay, Chief Bus. Dev. Officer
Alastair Benbow, Chief Dev. & Medical Officer
Kenneth Scrimgeour, Chief Commercial Officer
- Contact Info
Phone: (31) 1895 826 600
Amsterdam, 1101 CA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.